Advertisement

Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs

  • A. Chastang
  • S. Renet
  • J. Corny
  • H. Beaussier
  • A. Petre
  • A. Lillo-Lelouet
  • T. T. Phan Thi
  • Y. BézieEmail author
Research Article
  • 45 Downloads

Abstract

Background Citalopram and escitalopram can both induce dose-dependent QT prolongation. The risk of arrhythmia may be increased with concomitant use of other drugs that induce QT prolongation. Objective To evaluate the prevalence and impact of pharmacist interventions on the combination of citalopram or escitalopram with other drugs that induce QT prolongation. Setting A French hospital with 517 computerized beds. Method All cardiac adverse drug reactions (ADRs) related to citalopram or escitalopram reported to the French pharmacovigilance database (FPDB) were analyzed. Then, over a 6-month period, all computerized prescriptions including citalopram or escitalopram and drug–drug interactions (DDI) were analyzed by pharmacists using a computerized provider order entry system (DXCare®, Medasys). Results Only 27 cardiac ADRs related to citalopram or escitalopram were reported in the database. Among the 57,857 prescriptions and 2116 contraindicated DDIs (3.7 %) that were analyzed. 444 DDIs (0.8 %) were considered to be clinically relevant by pharmacists and physicians and 168 (i.e., approximately 30 %) were related to a combination including citalopram or escitalopram. Most of the prescriptions related to DDIs including citalopram or escitalopram were discontinued in response to a pharmacist intervention when initiated during the hospital stay. Conclusion A high number of hospital prescriptions including citalopram or escitalopram with another QT-prolonging drug occurred, highlighting the importance of involvement of clinical pharmacists in prevention of potential ADRs related to such contraindications.

Keywords

Citalopram Contraindicated drug–drug interactions Drug safety Pharmacist intervention QT-prolonging drugs 

Notes

Acknowledgements

None.

Conflicts of interest

The authors declare no conflicts of interest.

Funding

None to declare.

References

  1. 1.
    Sultana J, Cutroneo P, Trifiro G. Clinical and economic burden of adverse drug reactions. J Pharmacol Pharmacother. 2013;4(Suppl 1):S73–7.CrossRefGoogle Scholar
  2. 2.
    Sikdar KC, Dowden J, Alaghehbandan R, MacDonald D, Peter P, et al. Adverse drug reactions in elderly hospitalized patients: a 12-year population-based retrospective cohort study. Ann Pharmacother. 2012;46(7–8):960–71.CrossRefGoogle Scholar
  3. 3.
    Tache SV, Sonnichsen A, Ashcroft DM. Prevalence of adverse drug events in ambulatory care: a systematic review. Ann Pharmacother. 2011;45(7–8):977–89.CrossRefGoogle Scholar
  4. 4.
    Bouvy JC, De Bruin ML, Koopmanschap MA. Epidemiology of adverse drug reactions in Europe: a review of recent observational studies. Drug Saf. 2015;38(5):437–53.CrossRefGoogle Scholar
  5. 5.
    Lazarou J, Pomeranz B, Corey P. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998;79:1200–5.CrossRefGoogle Scholar
  6. 6.
    Trifiro G, Pariente A, Coloma PM, Kors JA, Polimeni G, et al. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? Pharmacoepidemiol Drug Saf. 2009;18(12):1176–84.CrossRefGoogle Scholar
  7. 7.
    Lam R. Antidepressants and QTc prolongation. J Psychiatry Neurosci. 2013;38(2):E5–6.CrossRefGoogle Scholar
  8. 8.
    Hasnain M, Howland RH, Vieweg WV. Escitalopram and QTc prolongation. J Psychiatry Neurosci. 2013;38(4):E11.CrossRefGoogle Scholar
  9. 9.
    Álvarez E, Vieira S, Garcia-Moll X. Citalopram, escitalopram and prolonged QT: warning or alarm? Rev Psiquiatr Salud Ment. 2014;7(3):147–50.CrossRefGoogle Scholar
  10. 10.
    Coughtrie A, Behr E, Layton D, Marshall V, Camm AJ, et al. Drugs and life-threatening ventricular arrhythmia risk: results from the DARE study cohort. BMJ Open. 2017;7(10):e016627.CrossRefGoogle Scholar
  11. 11.
    Leape LL, Bates DW, Cullen DJ, Cooper J, Demonaco HJ, et al. Systems analysis of adverse drug events. ADE Prevention Study Group. JAMA. 1995;274(1):35–43.CrossRefGoogle Scholar
  12. 12.
    Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf. 2007;30(10):911–8.CrossRefGoogle Scholar
  13. 13.
    Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm. 2004;61(4):380–5.PubMedGoogle Scholar
  14. 14.
    Kannry J. Effect of e-prescribing systems on patient safety. Mt Sinai J Med. 2011;78(6):827–33.CrossRefGoogle Scholar
  15. 15.
    Kaushal R, Kern LM, Barron Y, Quaresimo J, Abramson EL. Electronic prescribing improves medication safety in community-based office practices. J Gen Intern Med. 2010;25(6):530–6.CrossRefGoogle Scholar
  16. 16.
    Nuckols TK, Smith-Spangler C, Morton SC, Asch SM, Patel VM, et al. The effectiveness of computerized order entry at reducing preventable adverse drug events and medication errors in hospital settings: a systematic review and meta-analysis. Syst Rev. 2014;3:56.CrossRefGoogle Scholar
  17. 17.
    Footracer KG. Alert fatigue in electronic health records. JAAPA. 2015;28(7):41–2.CrossRefGoogle Scholar
  18. 18.
    Bates DW, Leape LL, Cullen DJ, Laird N, Petersen LA, et al. Effect of computerized physician order entry and a team intervention on prevention of serious medication errors. JAMA. 1998;280(15):1311–6.CrossRefGoogle Scholar
  19. 19.
    Bobb A, Gleason K, Husch M, Feinglass J, Yarnold PR, et al. The epidemiology of prescribing errors: the potential impact of computerized prescriber order entry. Arch Intern Med. 2004;164(7):785–92.CrossRefGoogle Scholar
  20. 20.
    Anthierens S, Tansens A, Petrovic M, Christiaens T. Qualitative insights into general practitioners views on polypharmacy. BMC Fam Pract. 2010;11:65.CrossRefGoogle Scholar
  21. 21.
    Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart. 2003;89(11):1363–72.CrossRefGoogle Scholar
  22. 22.
    Tampi RR, Balderas M, Carter KV, Tampi DJ, Moca M, et al. Citalopram, QTc prolongation, and torsades de pointes. Psychosomatics. 2015;56(1):36–43.CrossRefGoogle Scholar
  23. 23.
    Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. Ann Pharmacother. 2013;47(10):1330–41.CrossRefGoogle Scholar
  24. 24.
    Wisniowska B, Tylutki Z, Wyszogrodzka G, Polak S. Drug-drug interactions and QT prolongation as a commonly assessed cardiac effect—comprehensive overview of clinical trials. BMC Pharmacol Toxicol. 2016;17:12.CrossRefGoogle Scholar
  25. 25.
    Li M, Ramos LG. Drug-induced QT prolongation and torsades de pointes. P T. 2017;42(7):473–7.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–96.CrossRefGoogle Scholar
  27. 27.
    Pushkin R, Frassetto L, Tsourounis C, Segal ES, Kim S. Improving the reporting of adverse drug reactions in the hospital setting. Postgrad Med. 2010;122(6):154–64.CrossRefGoogle Scholar
  28. 28.
    Khan SA, Goyal C, Chandel N, Rafi M. Knowledge, attitudes, and practice of doctors to adverse drug reaction reporting in a teaching hospital in India: an observational study. J Nat Sci Biol Med. 2013;4(1):191–6.CrossRefGoogle Scholar
  29. 29.
    Allen LaPointe NM, Curtis LH, Chan KA, Kramer JM, Lafata JE, et al. Frequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf. 2006;15(6):361–8.CrossRefGoogle Scholar
  30. 30.
    Meid AD, Bighelli I, Machler S, Mikus G, Carra G, et al. Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol. 2017;7(12):251–64.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Pharmacy DepartmentGroupe hospitalier Paris Saint-JosephParisFrance
  2. 2.Clinical Pharmacy DepartmentUniversity Paris SaclayParisFrance
  3. 3.Clinical Research CenterGroupe hospitalier Paris Saint-JosephParisFrance
  4. 4.Centre Régional de PharmacoVigilanceHôpital Européen Georges PompidouParisFrance

Personalised recommendations